Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
42,400,943
-
Shares change
-
-730,323
-
Total reported value, excl. options
-
$423,114,024
-
Value change
-
-$5,780,444
-
Put/Call ratio
-
4.77%
-
Number of buys
-
70
-
Number of sells
-
-63
-
Price
-
$9.98
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2018
167 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2018.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42,400,943 shares
of 236,234,693 outstanding shares and own 17.9% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5,015,035 shares), Nantahala Capital Management, LLC (4,523,111 shares), Novo Holdings A/S (3,100,000 shares), EAGLE ASSET MANAGEMENT INC (2,824,403 shares), VANGUARD GROUP INC (2,575,354 shares), PERCEPTIVE ADVISORS LLC (2,215,400 shares), CARILLON TOWER ADVISERS, INC. (2,060,804 shares), STATE STREET CORP (1,930,404 shares), RENAISSANCE TECHNOLOGIES LLC (1,874,600 shares), and MORGAN STANLEY (1,391,367 shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.